WASHINGTON, June 27, 2021 /PRNewswire/ -- DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19. Additional findings from the trial were presented today at...
from PR Newswire: https://ift.tt/3hbdAOD
No comments:
Post a Comment